SHOCKWAVE MEDICAL INC (SWAV) Stock Fundamental Analysis

NASDAQ:SWAV • US82489T1043

334.75 USD
-0.08 (-0.02%)
At close: May 30, 2024
334.8 USD
+0.05 (+0.01%)
After Hours: 5/30/2024, 8:19:22 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

SWAV gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. SWAV has an excellent financial health rating, but there are some minor concerns on its profitability. SWAV is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make SWAV suitable for growth investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • SWAV had positive earnings in the past year.
  • In the past year SWAV had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: SWAV reported negative net income in multiple years.
  • In multiple years SWAV reported negative operating cash flow during the last 5 years.
SWAV Yearly Net Income VS EBIT VS OCF VS FCFSWAV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

1.2 Ratios

  • SWAV's Return On Assets of 9.95% is amongst the best of the industry. SWAV outperforms 93.23% of its industry peers.
  • SWAV's Return On Equity of 21.76% is amongst the best of the industry. SWAV outperforms 95.31% of its industry peers.
  • With an excellent Return On Invested Capital value of 8.81%, SWAV belongs to the best of the industry, outperforming 88.54% of the companies in the same industry.
Industry RankSector Rank
ROA 9.95%
ROE 21.76%
ROIC 8.81%
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
SWAV Yearly ROA, ROE, ROICSWAV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

1.3 Margins

  • With an excellent Profit Margin value of 20.76%, SWAV belongs to the best of the industry, outperforming 94.79% of the companies in the same industry.
  • With an excellent Operating Margin value of 20.52%, SWAV belongs to the best of the industry, outperforming 94.27% of the companies in the same industry.
  • The Gross Margin of SWAV (86.99%) is better than 96.35% of its industry peers.
  • SWAV's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 20.52%
PM (TTM) 20.76%
GM 86.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
SWAV Yearly Profit, Operating, Gross MarginsSWAV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • SWAV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for SWAV has been increased compared to 1 year ago.
  • SWAV has a worse debt/assets ratio than last year.
SWAV Yearly Shares OutstandingSWAV Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
SWAV Yearly Total Debt VS Total AssetsSWAV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 10.26 indicates that SWAV is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 10.26, SWAV belongs to the best of the industry, outperforming 86.98% of the companies in the same industry.
  • SWAV has a debt to FCF ratio of 4.41. This is a neutral value as SWAV would need 4.41 years to pay back of all of its debts.
  • SWAV's Debt to FCF ratio of 4.41 is amongst the best of the industry. SWAV outperforms 82.81% of its industry peers.
  • SWAV has a Debt/Equity ratio of 0.97. This is a neutral value indicating SWAV is somewhat dependend on debt financing.
  • SWAV has a Debt to Equity ratio of 0.97. This is in the lower half of the industry: SWAV underperforms 76.56% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 4.41
Altman-Z 10.26
ROIC/WACC0.94
WACC9.36%
SWAV Yearly LT Debt VS Equity VS FCFSWAV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

  • SWAV has a Current Ratio of 13.81. This indicates that SWAV is financially healthy and has no problem in meeting its short term obligations.
  • SWAV has a better Current ratio (13.81) than 97.92% of its industry peers.
  • A Quick Ratio of 12.61 indicates that SWAV has no problem at all paying its short term obligations.
  • SWAV's Quick ratio of 12.61 is amongst the best of the industry. SWAV outperforms 97.40% of its industry peers.
Industry RankSector Rank
Current Ratio 13.81
Quick Ratio 12.61
SWAV Yearly Current Assets VS Current LiabilitesSWAV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • SWAV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.34%, which is quite good.
  • SWAV shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.44%.
  • SWAV shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 126.31% yearly.
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%

3.2 Future

  • Based on estimates for the next years, SWAV will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.56% on average per year.
  • Based on estimates for the next years, SWAV will show a very strong growth in Revenue. The Revenue will grow by 20.10% on average per year.
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SWAV Yearly Revenue VS EstimatesSWAV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
SWAV Yearly EPS VS EstimatesSWAV Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • SWAV is valuated quite expensively with a Price/Earnings ratio of 78.21.
  • Based on the Price/Earnings ratio, SWAV is valued a bit cheaper than 67.19% of the companies in the same industry.
  • SWAV's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.16.
  • With a Price/Forward Earnings ratio of 53.09, SWAV can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SWAV indicates a somewhat cheap valuation: SWAV is cheaper than 68.75% of the companies listed in the same industry.
  • SWAV is valuated expensively when we compare the Price/Forward Earnings ratio to 28.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 78.21
Fwd PE 53.09
SWAV Price Earnings VS Forward Price EarningsSWAV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, SWAV is valued a bit cheaper than 67.19% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, SWAV is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 75.65
EV/EBITDA 66.43
SWAV Per share dataSWAV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • SWAV has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as SWAV's earnings are expected to grow with 24.15% in the coming years.
PEG (NY)2.17
PEG (5Y)N/A
EPS Next 2Y27.65%
EPS Next 3Y24.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for SWAV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SHOCKWAVE MEDICAL INC

NASDAQ:SWAV (5/30/2024, 8:19:22 PM)

After market: 334.8 +0.05 (+0.01%)

334.75

-0.08 (-0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-06
Earnings (Next)08-05
Inst Owners10.85%
Inst Owner Change0%
Ins Owners5.23%
Ins Owner Change0%
Market Cap12.57B
Revenue(TTM)787.98M
Net Income(TTM)163.55M
Analysts53.75
Price Target330.75 (-1.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.32%
Min EPS beat(2)27.98%
Max EPS beat(2)44.66%
EPS beat(4)3
Avg EPS beat(4)18.35%
Min EPS beat(4)-12.88%
Max EPS beat(4)44.66%
EPS beat(8)7
Avg EPS beat(8)24.97%
EPS beat(12)11
Avg EPS beat(12)73.56%
EPS beat(16)13
Avg EPS beat(16)54.46%
Revenue beat(2)1
Avg Revenue beat(2)1.53%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)3.29%
Revenue beat(4)2
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-1.27%
Max Revenue beat(4)3.29%
Revenue beat(8)5
Avg Revenue beat(8)2.94%
Revenue beat(12)9
Avg Revenue beat(12)5.4%
Revenue beat(16)13
Avg Revenue beat(16)8.23%
PT rev (1m)2.57%
PT rev (3m)25.91%
EPS NQ rev (1m)-2.66%
EPS NQ rev (3m)-2.74%
EPS NY rev (1m)6.44%
EPS NY rev (3m)16.18%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)0.36%
Revenue NY rev (1m)0.78%
Revenue NY rev (3m)0.99%
Valuation
Industry RankSector Rank
PE 78.21
Fwd PE 53.09
P/S 15.95
P/FCF 75.65
P/OCF 63.5
P/B 16.72
P/tB 20.26
EV/EBITDA 66.43
EPS(TTM)4.28
EY1.28%
EPS(NY)6.31
Fwd EY1.88%
FCF(TTM)4.42
FCFY1.32%
OCF(TTM)5.27
OCFY1.57%
SpS20.99
BVpS20.03
TBVpS16.52
PEG (NY)2.17
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 9.95%
ROE 21.76%
ROCE 10.42%
ROIC 8.81%
ROICexc 26.17%
ROICexgc 34.98%
OM 20.52%
PM (TTM) 20.76%
GM 86.99%
FCFM 21.08%
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 4.41
Debt/EBITDA 4.22
Cap/Depr 270.11%
Cap/Sales 4.03%
Interest Coverage 30.21
Cash Conversion 114.09%
Profit Quality 101.56%
Current Ratio 13.81
Quick Ratio 12.61
Altman-Z 10.26
F-Score5
WACC9.36%
ROIC/WACC0.94
Cap/Depr(3y)384.02%
Cap/Depr(5y)409.93%
Cap/Sales(3y)4.85%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%
EBIT growth 1Y8.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.79%
EBIT Next 3Y41.48%
EBIT Next 5Y38.45%
FCF growth 1Y635%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y478.63%
OCF growth 3YN/A
OCF growth 5YN/A

SHOCKWAVE MEDICAL INC / SWAV FAQ

What is the fundamental rating for SWAV stock?

ChartMill assigns a fundamental rating of 6 / 10 to SWAV.


What is the valuation status for SWAV stock?

ChartMill assigns a valuation rating of 4 / 10 to SHOCKWAVE MEDICAL INC (SWAV). This can be considered as Fairly Valued.


What is the profitability of SWAV stock?

SHOCKWAVE MEDICAL INC (SWAV) has a profitability rating of 6 / 10.


Can you provide the expected EPS growth for SWAV stock?

The Earnings per Share (EPS) of SHOCKWAVE MEDICAL INC (SWAV) is expected to grow by 36.11% in the next year.